Login to Your Account

EBG petitions FDA to limit term of review of combo product appeals

By Mark McCarty
Regulatory Editor

Wednesday, March 15, 2017

The regulatory law firm of Epstein Becker Green (EBG) has petitioned the FDA to set a limit to the number of days the agency can take to review petitions regarding combo product designations, stating that as matters stand, the agency is “unaccountable for egregious delays in decision-making.”

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription